Cancer drug prices fall sharply, but can patients afford the full cost of treatment?
Indian markets moved lower in a quarterly results development.
· Business Today Mkts
The government’s trade margin cap has reduced prices of more than 1,000 anti-cancer medicine formulations, with estimated annual savings of ₹3,502 crore. But diagnostics, hospitalisation and prolonged treatment continue to add to the financial burden.
The analysis
Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- Sectors in the story: Financial Services.
Financial Services
1M +1.9% · 3M -8.6%
Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
FPIs turn net buyers; pour Rs 53,739 crore in D-Street in Nov so far
Blackstone set to become key investor in IIFL Finance with 15% stake
MRF Q2 Results: Net Profit Falls 28% To Rs 369 Crore, Declares Dividend; Check Record Date
Q2 Results Live Updates: Tata Power, Hindustan Copper, GRSE, Triveni Turbine In Focus
Kalyan Jewellers shares jump 10% post Q2 results; 'Buy' stock, says MOFSL